 Connection
Satish Garg to Insulin, Long-Acting
This is a "connection" page, showing publications Satish Garg has written about Insulin, Long-Acting.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.250 |
|
|
|
-
Ji L, Zhang P, Zhu D, Li X, Ji J, Lu J, Guo X, Jia W, Weng J, Wu Y, Yang W, Zou D, Zhou Z, Pan C, Gao Y, Garg SK. Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: Real-life use of basal insulin in China. Diabetes Obes Metab. 2017 06; 19(6):822-830.
Score: 0.546
-
Davis SN, Wei W, Garg S. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting. Endocr Pract. 2011 Nov-Dec; 17(6):845-52.
Score: 0.376
-
Shah VN, Moser EG, Blau A, Dhingra M, Garg SK. The future of basal insulin. Diabetes Technol Ther. 2013 Sep; 15(9):727-32.
Score: 0.107
-
Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, Renard E, Russell-Jones D, Philotheou A, Francisco AM, Pei H, Bode B. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012 Apr 21; 379(9825):1489-97.
Score: 0.097
-
Garg SK, Moser EG. How basal insulin analogs have changed diabetes care. Diabetes Technol Ther. 2011 Jun; 13 Suppl 1:S1-4.
Score: 0.091
-
Garg S, Moser E, Dain MP, Rodionova A. Clinical experience with insulin glargine in type 1 diabetes. Diabetes Technol Ther. 2010 Nov; 12(11):835-46.
Score: 0.088
-
Garg S, Ampudia-Blasco FJ, Pfohl M. Rapid-acting insulin analogues in Basal-bolus regimens in type 1 diabetes mellitus. Endocr Pract. 2010 May-Jun; 16(3):486-505.
Score: 0.085
-
Garg SK. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review. Diabetes Technol Ther. 2010 Jan; 12(1):11-24.
Score: 0.083
-
Garg SK, Mathieu C, Rais N, Gao H, Tobian JA, Gates JR, Ferguson JA, Webb DM, Berclaz PY. Two-year efficacy and safety of AIR inhaled insulin in patients with type 1 diabetes: An open-label randomized controlled trial. Diabetes Technol Ther. 2009 Sep; 11 Suppl 2:S5-S16.
Score: 0.081
-
Garg SK, Hirsch IB, Skyler JS. Insulin glargine and cancer--an unsubstantiated allegation. Diabetes Technol Ther. 2009 Aug; 11(8):473-6.
Score: 0.080
-
Garg SK, Naik RG. Long-acting insulin analogs versus human insulins. Diabetes Technol Ther. 2008 Oct; 10(5):331-2.
Score: 0.076
-
Garg S, Kelly WC, Garg S. Insulin glargine and glulisine SoloSTAR pens for the treatment of diabetes. Expert Rev Med Devices. 2008 Mar; 5(2):113-23.
Score: 0.073
-
Garg SK. New insulin analogues. Diabetes Technol Ther. 2005 Oct; 7(5):813-7.
Score: 0.062
-
Dixon B, Peter Chase H, Burdick J, Fiallo-Scharer R, Walravens P, Klingensmith G, Rewers M, Garg SK. Use of insulin glargine in children under age 6 with type 1 diabetes. Pediatr Diabetes. 2005 Sep; 6(3):150-4.
Score: 0.061
-
Garg SK, Gottlieb PA, Hisatomi ME, D'Souza A, Walker AJ, Izuora KE, Chase HP. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract. 2004 Oct; 66(1):49-56.
Score: 0.058
-
Garg SK, Paul JM, Karsten JI, Menditto L, Gottlieb PA. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes. Diabetes Technol Ther. 2004 Oct; 6(5):589-95.
Score: 0.058
-
Garg S, Chase HP. Treatment of adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2004 May; 17(5):805-6.
Score: 0.056
-
Garg SK, Walker AJ, Hoff HK, D'Souza AO, Gottlieb PA, Chase HP. Glycemic parameters with multiple daily injections using insulin glargine versus insulin pump. Diabetes Technol Ther. 2004 Feb; 6(1):9-15.
Score: 0.055
-
Chase HP, Dixon B, Pearson J, Fiallo-Scharer R, Walravens P, Klingensmith G, Rewers M, Garg SK. Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin. J Pediatr. 2003 Dec; 143(6):737-40.
Score: 0.054
-
Weinstock RS, Bode BW, Garg SK, Klonoff DC, El Sanadi C, Geho WB, Muchmore DB, Penn MS. Reduced hypoglycaemia using liver-targeted insulin in individuals with type 1 diabetes. Diabetes Obes Metab. 2022 09; 24(9):1762-1769.
Score: 0.049
-
Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, Santiago OM, Kolaczynski JW. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care. 2005 Mar; 28(3):533-8.
Score: 0.015
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|